Interferon Gamma-1b in Friedreich Ataxia (FRDA)

Study Objectives: Primary: • To assess the effect of Interferon Gamma-1b (IFN-g) on increasing frataxin expression and protein in children with FRDA. Secondary: * To assess the effect of IFN-g on neurological outcomes (FARS, performance measures, and hearing) in subjects with FRDA. * To assess the effectiveness of IFN-g on quality of life in subjects with FRDA. * To assess the safety and tolerability of IFN-g at the currently approved dose in the FRDA population. Study Phases: Screening - During screening, subjects will be assessed for inclusion and exclusion criteria. Intervention - Subjects will begin treatment at baseline visit and the dose of study medication will be increased to the maximum dose over four weeks. The subjects will be maintained at the maximum dose for 8 weeks. After 12 weeks, treatment will stop. Study medication will be administered via subcutaneous injections three times per week for 12 weeks. Follow-up - Follow-up visits will occur at 7 and 28 days after the subject has completed the 12 weeks of active treatment.